Journal
LUPUS SCIENCE & MEDICINE
Volume 9, Issue 1, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/lupus-2022-000772
Keywords
systemic lupus erythematosus; glucocorticoids; outcome assessment; health care; epidemiology
Categories
Funding
- JSPS KAKENHI [JP19K1053]
Ask authors/readers for more resources
The objective of this study was to explore the factors associated with GC-free treatment status in patients with SLE. The results showed that even in patients with long disease duration, GC-free treatment status might be related to no chronic damage accrual.
Objective It is still unclear how glucocorticoids (GCs) affect the long-term clinical course of patients with SLE. The objective of this study is to explore the factors associated with GC-free treatment status. Methods Using data from the lupus registry of nationwide institutions, GC dose at registration was compared between short, middle and long disease durations of <5, 5-20 and >= 20 years, respectively. After excluding patients who never used GC, we evaluated the relationship between GC-free status and chronic damage using Systemic Lupus International Collaborating Clinics Damage Index. Results GC doses at enrolment of the 1019 patients were as follows: GC-free in 101 (10%); 0 Conclusion Even in the patients with long disease duration, one-point GC-free treatment status might be related to no chronic damage accrual.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available